Boston/Cambridge Group

New Funding Models for Translational Medicine: The Boston/Cambridge BioFinance Working Group

The MIT Laboratory for Financial Engineering hosted an invitation-only meeting at MIT on February 23, 2015 to explore new business models and financial vehicles for raising and deploying funds for early-stage biomedical research and drug development in a scalable and profitable manner. The meeting brought together a small group of stakeholders from financial institutions, institutional investors, foundations and endowments, and local-area academic medical centers and university research laboratories to engage in active dialogue regarding specific funding needs, potential business and legal structures for pooling intellectual property, and new sources of capital to fund such portfolios.

Meeting Agenda
9:30am – 10:00am Registration and Continental Breakfast
10:00am – 10:30am Welcome and Introductions
Bob Langer, Pablo Legorreta, and Andrew W. Lo
10:30am – 11:45am Recent Innovations and Funding Needs
Ed Benz (Dana Farber Cancer Institute), Bruce Chabner (MGH), Jeffrey Flier (Harvard Medical School), Manolis Kellis (MIT), Phil Sharp (MIT Koch Institute), Bob Weinberg (Whitehead Institute and MIT Koch Institute)
11:45am – 12:00pm Break
12:00pm – 1:00pm Lunch Discussion: The Evolving Role of Nonprofits
Louis DeGennaro (Leukemia & Lymphoma Society), Ken Schaner (Schaner & Lubitz), Christiana Stamoulis (Unum Therapeutics)
1:00pm – 2:00pm Pharma/Bioetch/Academic Perspectives
Belen Carrillo-Rivas (Pfizer), Doug Cole (Flagship Ventures), Alan Crane (Polaris Partners), Ansbert Gadicke (MPM Capital), Marc Tessier-Lavigne (Rockefeller University), Robert Urban (J&J)
2:00pm – 2:15pm Break
2:15pm – 3:15pm Potential Business/Financing Structures
Mark Chalek (Beth Israel Deaconess Medical Center), Jennifer Goldstein (Silicon Valley Bank), Edward Jung (Intellectual Ventures), Lita Nelsen (MIT), Katrina Niehaus (Goldman Sachs), Issi Rozen (Broad Institute)
3:15pm – 3:30pm Break
3:30pm – 4:30pm Investor Perspectives
Gerald Chan (Morningside), Jim Reddoch (Royalty Pharma), Tom Rutledge (Magnetar Capital), Jake Xia (Harvard Management Company)
4:30pm – 5:00pm Wrap-Up and Next Steps